Nephrology

The data, which will be presented at a later time, may enable regulatory submission for accelerated approval to the FDA.

Jonathan Barratt, PhD, discusses his excitement surrounding data and programming at the American Society of Nephrology's Kidney Week 2024, with a focus on IgAN.

Kidney Compass: Navigating Clinical Trials is a multimedia podcast from HCPLive hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, aimed at exploring the latest in clinical trials and updates in nephrology.

This retrospective analysis examined the current management of early and late anemia in a representative sample of the kidney transplant population in Spain.

This September 2024 month in review spotlights our top coverage of recent nephrology pipeline updates, guidelines, and research.

Gross hematuria after COVID-19 mRNA vaccination was more likely in females, patients with IgAN/IgAV, and after the second and third vaccine doses.

Only 6.7% of patients with an abnormal protein dipstick test result had guideline-recommended follow-up albuminuria testing.

A study found pregnant patients with IgA nephropathy and adverse pregnancy outcomes were less likely to achieve proteinuria remission, though renal function remained unaffected.

Alcohol intake frequency was linked to a greater risk of IgAN, while dietary exposures like cheese, cereal, and sushi were associated with a reduced risk.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

Leveraging deceased donor kidney transplantation data, study results suggest DCD-V kidney transplantation has similar short- and long-term outcomes versus DCD-III and DBD.

Study results suggest C4d is associated with worse renal survival and disease progression to kidney failure in patients with primary IgA nephropathy.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

A new study found cannabis-containing cream may be effective at alleviating itch in patients with chronic kidney disease (CKD)-associated pruritus with no adverse events.

There was no difference in the incidence of BKPyV, CMV, or EBV in patients who received HCV NAT-positive donor kidneys versus those who received HCV NAT-negative donor kidneys.

Barratt reflects on recent therapeutic developments in IgAN, the most recent being the full FDA approval of sparsentan (Filspari), and the importance of preventing kidney failure.

The FDA has granted full approval to sparsentan (Filspari) for slowing kidney function decline in adults with IgAN at risk of disease progression based on PROTECT trial data.

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.

Findings from a recent national registry study suggest perioperative mortality after living kidney donation significantly declined in 2013-2022 compared with 1993-2002 and 2003-2012.

The majority of highly suspected COVID-19 vaccine-associated glomerular disease cases were diagnosed as immunoglobulin A nephropathy and eventually improved with treatment.